Agreement provides J&JPRD with Cellzome’s Amyloid Precursor Protein processing pathway map for one more year.

Cellzome, Ortho-McNeil Pharmaceutical, and its affiliate Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) extended their joint research program aimed at identifying new medicines for the treatment of Alzheimer’s disease for one year.

First announced in March 2005, the collaboration provides J&JPRD with Cellzome’s Amyloid Precursor Protein processing pathway map containing new drug targets, its chemical proteomics technology, and novel small molecules targeted at Gamma Secretase.

Previous articleStratagene Pays Third Wave $10.75M to Settle Infringement Case
Next articleOGT and Sanger Institute Work on a Test for Prenatal Syndromes